[{"address1": "12790 El Camino Real", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "760 593 4832", "website": "https://ventyxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.", "fullTimeEmployees": 74, "auditRisk": 2, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 2.51, "open": 2.55, "dayLow": 2.5, "dayHigh": 2.655, "regularMarketPreviousClose": 2.51, "regularMarketOpen": 2.55, "regularMarketDayLow": 2.5, "regularMarketDayHigh": 2.655, "beta": 0.578, "forwardPE": -1.0960699, "volume": 1488897, "regularMarketVolume": 1488897, "averageVolume": 1153374, "averageVolume10days": 1211750, "averageDailyVolume10Day": 1211750, "bid": 2.5, "ask": 2.54, "bidSize": 1000, "askSize": 1000, "marketCap": 176953232, "fiftyTwoWeekLow": 1.865, "fiftyTwoWeekHigh": 40.58, "fiftyDayAverage": 4.1913, "twoHundredDayAverage": 8.7768, "currency": "USD", "enterpriseValue": -114147968, "floatShares": 51004551, "sharesOutstanding": 70499296, "sharesShort": 8306506, "sharesShortPriorMonth": 8376045, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1178, "heldPercentInsiders": 0.03178, "heldPercentInstitutions": 0.95252, "shortRatio": 9.35, "shortPercentOfFloat": 0.138, "impliedSharesOutstanding": 77240304, "bookValue": 4.355, "priceToBook": 0.576349, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -192603008, "trailingEps": -3.24, "forwardEps": -2.29, "enterpriseToEbitda": 0.551, "52WeekChange": -0.9207952, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "VTYX", "underlyingSymbol": "VTYX", "shortName": "Ventyx Biosciences, Inc.", "longName": "Ventyx Biosciences, Inc.", "firstTradeDateEpochUtc": 1634823000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f523c464-d79a-3f62-beea-fdbd09f3b782", "messageBoardId": "finmb_672535556", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.51, "targetHighPrice": 21.0, "targetLowPrice": 5.0, "targetMeanPrice": 10.8, "targetMedianPrice": 9.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 302582016, "totalCashPerShare": 4.292, "ebitda": -207012992, "totalDebt": 11494000, "quickRatio": 20.819, "currentRatio": 22.001, "debtToEquity": 3.744, "returnOnAssets": -0.35911998, "returnOnEquity": -0.56764, "freeCashflow": -109898248, "operatingCashflow": -183226000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]